Cargando…
晚期非小细胞肺癌BRAF突变靶向治疗进展
Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105358/ https://www.ncbi.nlm.nih.gov/pubmed/30172272 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.10 |